Our Partners

We are collaborating on a number of clinical trials to provide evidence for the benefits that our products offer to patients.  Our current collaborators include:

The Wellcome Trust – supporting the PROFILE Study, which aims to demonstrate that a prognostic biomarker can enable delivery of personalised therapy in Crohn’s disease, and that this improves clinical outcomes.

The Wellcome Trust is a UK research charity established in 1936 with legacies from Sir Henry Wellcome to fund research to improve human and animal health. The Trust’s aim is to “achieve extraordinary improvements in health by supporting the brightest minds“ via the funding of biomedical research. With a £26.8 billion investment portfolio, The Wellcome trust is the UK’s largest provider of non-governmental funding for scientific research, and one of the largest providers in the world.

Crohn’s and Colitis Foundation  – supporting the PRECIOUS Study, a multi-centre, observational study of newly diagnosed IBD (CD or UC) patients. The Study aims to assess whether a prognostic biomarker can stratify IBD patients in the US

The Crohn’s & Colitis Foundation is a US-based, non-profit, volunteer-driven organization dedicated to finding cures for Crohn’s disease and ulcerative colitis, and to improving the quality of life of children and adults affected by these diseases. The foundation collaborates with healthcare providers to improve IBD quality of care, as well as educating, supporting, and empowering patients and their care givers through patient-centric education and advocacy programs.

Our PredictSURE® IBD test offers enhanced clinical trial design and delivery by stratifying patients into groups at high and low-risk of aggressive disease. This allows enrichment for poor prognosis patients, reducing trial size and cost. Ultimately, our technology has the potential to be developed into predictive tests to identify those patients who will benefit most from a therapeutic product.

Please contact us if you’d like to discuss a partnership